<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18332">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01931410</url>
  </required_header>
  <id_info>
    <org_study_id>Aşıcıoğlu-05</org_study_id>
    <nct_id>NCT01931410</nct_id>
  </id_info>
  <brief_title>The Effect of Rectal and Sublingual Misoprostol Administration in Postpartum or Intrapartum Haemorrhage at Elective Caesarean Delivery: a Randomized Controlled Trial</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul Bakirkoy Maternity and Children Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul Bakirkoy Maternity and Children Diseases Hospital</source>
  <oversight_info>
    <authority>Turkey: Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesis in this study is that administration of rectal and sublingual
      misoprostol decreases intrapartum and postpartum haemorrhage.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Postpartum Haemorrhage</measure>
    <time_frame>postpartum 24 hour</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">618</enrollment>
  <condition>ıntrapartum Haemorrhage</condition>
  <condition>Postpartum Haemorrhage</condition>
  <arm_group>
    <arm_group_label>sublingual</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>400 microgram mısoprostol will be administered sublıngually before elective caesarean</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rectal</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>rectal 600 mgr misoprostol will be administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>synpitan</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <arm_group_label>sublingual</arm_group_label>
    <arm_group_label>rectal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. live and singleton pregnancy

          2. Elective caesarean

          3. Gestational week greater than 37 weeks

          4. patient between 18-44 year old

        Exclusion Criteria:

          1. -multiple pregnancy

          2. Preeclampsia

          3. Gestational diabetes

          4. Macrosomia

          5. Oligohidraamnıos

          6. Polihidraamnıos

          7. Myoma

          8. Morbid obesity

          9. Coagulatıon defect (such as HELLP syndrome)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Berhan AŞICIOĞLU, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>T.C.S.B. Kanuni Sultan Süleyman Research Hospital</affiliation>
  </overall_official>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 24, 2014</lastchanged_date>
  <firstreceived_date>August 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul Bakirkoy Maternity and Children Diseases Hospital</investigator_affiliation>
    <investigator_full_name>Osman Aşıcıoğlu</investigator_full_name>
    <investigator_title>M.D. Obstetric and Gynecology</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
